Given the documented evidence that CD8+ T cells mitigate AD progression by suppressing hyperactivated microglia, this immunomodulatory effect may provide complementary therapeutic synergy to AR@ENV’s primary efficacy. This evidence concerns the gene CD8A and Alzheimer disease.